Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 136Cytarabine 106Cyclophosphamide 104Specimen Handling 94fludarabine 86Azacitidine 84Biopsy 71Rituximab 45Methotrexate 42Daunorubicin 41fludarabine phosphate 40Vincristine 35Magnetic Resonance Spectroscopy 35Dexamethasone 35blinatumomab 31Injections 31Decitabine 31Granulocyte Colony-Stimulating Factor 29Mycophenolic Acid 28Whole-Body Irradiation 27Idarubicin 27ibrutinib 26Tacrolimus 26Prednisone 26Etoposide 26Busulfan 25Melphalan 24Doxorubicin 24acalabrutinib 23Calcium Dobesilate 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TAK-243 × Other hematologic neoplasm × 90 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡